SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (525)8/19/1997 4:26:00 PM
From: Bhag Karamchandani   of 2173
 
Q. If AMLN could not fix the amount of insulin taken by the control group, in the trials submitted to FDA, without jeopardizing the participant's health , then, how would they do it in the next round of P3 trials. And if Amlyn does really counteract against the slow but cumulative effects of diabetes,particularly for individuals with poor control, then, how do any number of relatively short term P3 trials prove this one way or another. I am not a diabetic or shareholder but would like to see improved treatment options for TYPE 1 diabetics.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News